imiquimod has been researched along with B16 Melanoma in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 14 (60.87) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Aranda Lopez, P; Bialojan, A; Denny, M; Hartmann, AK; Langguth, P; Probst, HC; Radsak, MP; Rausch, J; Schild, H; Sohl, J; Yagita, H | 1 |
| Baldi, A; Chandra, R; Jyoti, K; Madan, J; Sharma, A; Sharma, D | 1 |
| Bellmann, L; Brinckerhoff, CE; Cappellano, G; Mullins, DW; Ortner, D; Prokopi, A; Schachtl-Riess, JF; Seretis, A; Stoitzner, P; Tripp, CH | 1 |
| Chang, SH; Chen, YJ; Chuang, KC; Huang, SW; Kao, JK; Kao, SH; Liang, SM; Shieh, JJ; Wang, HY; Wang, ST; Wu, CY | 1 |
| Du, J; Guan, E; Hu, Y; Ji, Z; Li, M; Tan, Z; Tao, J | 1 |
| Angel, M; Aparicio, B; Berzofsky, JA; Calvo, A; Egea, J; Lasarte, JJ; Llopiz, D; Redin, E; Repáraz, D; Ruiz, M; Sarobe, P; Silva, L; Stroncek, D | 1 |
| Bialojan, A; Denny, M; Langguth, P; Lopez, PA; Probst, HC; Radsak, MP; Rausch, J; Schild, H | 1 |
| Aiba, S; Fujimura, T; Furudate, S; Hidaka, T; Kakizaki, A; Kambayashi, Y | 1 |
| Alegre, N; Gazzaniga, S; Pozner, R; Rocco, R; Wainstok, R | 1 |
| Agorio, CI; Bascuas, T; Chabalgoity, JA; Mónaco, A; Moreno, M; Rimsky, G; Vola, M | 1 |
| Li, P; Li, Y; Lu, C; Ren, S; Wang, Q; Zhang, Y | 1 |
| Dong, X; Liu, M; Qin, X; Ren, S; Song, Y; Wang, Q; Yu, T; Zhang, W; Zhang, Y | 1 |
| Chen, WR; Howard, EW; Qu, J; Song, J; Wang, J; Wang, M; Wang, X; Zhou, B; Zhou, F | 1 |
| Alignani, D; Guruceaga, E; Hervas-Stubbs, S; Infante, S; Lasarte, JJ; Llopiz, D; Ruiz, M; Sarobe, P; Silva, L; Villanueva, L | 1 |
| Cho, JH; Choe, J; Choi, SS; Hahn, TW; Han, JA; Jung, YJ; Jung, YM; Kim, KC; Ko, HJ; Lee, HJ; Lee, KH; Lee, YS; Yoon, BI | 1 |
| Bulte, JW; Levitsky, HI; Long, CM; van Laarhoven, HW | 1 |
| Akira, S; Diebold, SS; Morel, Y; Paturel, C; Rajagopal, D; Uematsu, S | 1 |
| Aldrich, W; Ponnazhagan, S; Triozzi, PL | 1 |
| Aranda, F; Bezunartea, J; Borrás-Cuesta, F; Díaz-Valdés, N; Durantez, M; Lasarte, JJ; Llopiz, D; Mansilla, C; Martínez, M; Prieto, J; Riezu-Boj, JI; Ruiz, M; Sarobe, P | 1 |
| Boczkowski, D; Dannull, J; Gilboa, E; McLaughlin, C; Nair, S; Su, Z; Vieweg, J; Weizer, A | 1 |
| Bruhn, KW; Craft, N; Liau, LM; Lin, JW; Miller, JF; Nguyen, BD; Prins, R | 1 |
| Bruhn, KW; Craft, N; Khan-Farooqi, H; Koya, RC; Liau, LM; Miller, JF; Prins, RM; Stripecke, R | 1 |
| Bendandi, M; del Olmo, J; Inoges, S; López-Diaz de Cerio, A; Marquina, M; Melero, I; Redondo, P | 1 |
23 other study(ies) available for imiquimod and B16 Melanoma
| Article | Year |
|---|---|
Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice.
Topics: Administration, Cutaneous; Allografts; Animals; CD27 Ligand; CD40 Ligand; Cytotoxicity, Immunologic; Gene Expression; Graft Rejection; Imiquimod; Immunization; Immunologic Memory; Immunotherapy; Melanoma, Experimental; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Ovalbumin; Skin; Skin Neoplasms; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Helper-Inducer; Toll-Like Receptor 7 | 2019 |
Imiquimod-oleic acid prodrug-loaded cream reduced drug crystallinity and induced indistinguishable cytotoxicity and apoptosis in mice melanoma tumour.
Topics: Administration, Topical; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Crystallization; Drug Delivery Systems; Imiquimod; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Oleic Acid; Prodrugs; Skin Cream | 2019 |
A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Imiquimod; Indoles; Killer Cells, Natural; Lymphocytes, Tumor-Infiltrating; Male; Melanoma, Experimental; Membrane Glycoproteins; Mice; Mutation; Natural Killer T-Cells; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; T-Lymphocytes; Toll-Like Receptor 7 | 2020 |
Imiquimod Exerts Antitumor Effects by Inducing Immunogenic Cell Death and Is Enhanced by the Glycolytic Inhibitor 2-Deoxyglucose.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxyglucose; Drug Synergism; Glycolysis; Humans; Imiquimod; Immunogenic Cell Death; Male; Melanoma, Experimental; Mice; Skin Neoplasms | 2020 |
Multi-functional nanocomplex codelivery of Trp2 and R837 to activate melanoma-specific immunity.
Topics: Adjuvants, Immunologic; Alginates; Animals; beta-Cyclodextrins; Cancer Vaccines; Cell Line, Tumor; Cytokines; Dendritic Cells; Drug Carriers; Drug Compounding; Female; Hydrophobic and Hydrophilic Interactions; Imiquimod; Lectins, C-Type; Mannose; Mannose Receptor; Mannose-Binding Lectins; Melanoma, Experimental; Membrane Proteins; Mice, Inbred C57BL; Nanoparticles; Peptide Fragments; Receptors, Cell Surface; Solubility; T-Lymphocytes, Helper-Inducer | 2020 |
Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.
Topics: Adjuvants, Immunologic; Animals; Axl Receptor Tyrosine Kinase; c-Mer Tyrosine Kinase; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Female; Gene Expression Regulation, Neoplastic; Humans; Imiquimod; Immunogenicity, Vaccine; Immunotherapy; Interleukin-10; Lymphocytes, Tumor-Infiltrating; Male; Melanoma, Experimental; Mice; Mice, Transgenic; Poly I-C; Prostatic Neoplasms; Proto-Oncogene Proteins; Pyrimidines; Quinolines; Receptor Protein-Tyrosine Kinases; Up-Regulation | 2021 |
Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antineoplastic Agents, Immunological; CTLA-4 Antigen; Drug Synergism; Flow Cytometry; Humans; Imiquimod; Immunologic Memory; Immunotherapy; Melanoma, Experimental; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Ovalbumin; Peptide Fragments; Skin Neoplasms; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Toll-Like Receptor 7; Xenograft Model Antitumor Assays | 2017 |
Immunomodulatory Effect of Imiquimod Through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas.
Topics: Aminoquinolines; Animals; CD11b Antigen; Cell Line, Tumor; Chemokine CCL22; Down-Regulation; Female; Forkhead Transcription Factors; Imiquimod; Immunologic Factors; Macrophages; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; T-Lymphocytes, Regulatory; Tumor Burden; Tumor Microenvironment | 2017 |
Selective hemangioma cell dysfunction and apoptosis triggered by in vitro treatment with imiquimod.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Survival; Cellular Senescence; Cytoskeleton; Endothelial Cells; Hemangioma; Humans; Imiquimod; Melanoma, Experimental; Mice; Skin Neoplasms; Stress Fibers | 2018 |
TLR7 agonist in combination with Salmonella as an effective antimelanoma immunotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Female; Imiquimod; Immunotherapy; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Microbial Viability; Neoplasm Metastasis; Salmonella typhi; Survival Analysis; Toll-Like Receptor 7; Treatment Outcome; Tumor Burden; Tumor Microenvironment | 2018 |
[Imiquimod combined with dendritic cell vaccine decreases Treg proportion and enhances anti-tumor responses in mice bearing melanoma].
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Cancer Vaccines; Dendritic Cells; Granulocyte-Macrophage Colony-Stimulating Factor; Imiquimod; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Ovalbumin; T-Lymphocytes, Regulatory; Toll-Like Receptor 7 | 2017 |
Imiquimod enhances the potency of an exogenous BM-DC based vaccine against mouse melanoma.
Topics: Adjuvants, Immunologic; Animals; Bone Marrow Cells; Cancer Vaccines; Cell Movement; Cells, Cultured; Dendritic Cells; Female; Imiquimod; Lymph Nodes; Melanoma, Experimental; Mice; Mice, Inbred C57BL; T-Lymphocytes, Regulatory; Toll-Like Receptor 7 | 2018 |
BSA-bioinspired gold nanorods loaded with immunoadjuvant for the treatment of melanoma by combined photothermal therapy and immunotherapy.
Topics: Adjuvants, Immunologic; Animals; Cattle; Cell Line, Tumor; Cell Survival; Cetrimonium; Combined Modality Therapy; Cytokines; Gold; HSP70 Heat-Shock Proteins; Imiquimod; Immunotherapy; Infrared Rays; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Nanotubes; Phototherapy; Polyethylene Glycols; Serum Albumin, Bovine | 2018 |
IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.
Topics: Aminoquinolines; Animals; B7-H1 Antigen; Cancer Vaccines; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Female; Humans; Imiquimod; Immunomodulation; Immunophenotyping; Immunotherapy; Interleukin-10; Lymphocyte Activation; Melanoma, Experimental; Mice; Mice, Transgenic; Neoplasms; Phenotype; T-Lymphocytes; Vaccination; Xenograft Model Antitumor Assays | 2017 |
The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Autophagy; Cell Death; Chemoradiotherapy; Disease Models, Animal; Imiquimod; Melanoma, Experimental; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Toll-Like Receptor 7 | 2017 |
Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antigen Presentation; Cancer Vaccines; Dendritic Cells; Female; Ferric Compounds; Granulocyte-Macrophage Colony-Stimulating Factor; Image Processing, Computer-Assisted; Imiquimod; Lymph Nodes; Magnetic Resonance Imaging; Magnetics; Melanoma, Experimental; Mice; Mice, Inbred C57BL | 2009 |
Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antineoplastic Agents; Cancer Vaccines; Dendritic Cells; Dose-Response Relationship, Drug; Imidazoles; Imiquimod; Interferon Type I; Melanoma, Experimental; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Quinolines; Receptor, Interferon alpha-beta; RNA; Toll-Like Receptor 7; Tumor Cells, Cultured | 2010 |
Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Cancer Vaccines; Cells, Cultured; Dendritic Cells; Dependovirus; DNA; Female; Imiquimod; Interleukin-10; Melanoma, Experimental; Membrane Proteins; Mice; Mice, Inbred C57BL; Oligodeoxyribonucleotides; Peptide Fragments; T-Lymphocytes, Regulatory; Toll-Like Receptor 7; Toll-Like Receptor 9 | 2010 |
Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antibodies; Antibody Affinity; Antigens, Neoplasm; CD4 Antigens; Female; Imiquimod; Immunity, Innate; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Ovalbumin; Poly I-C; T-Lymphocytes; Thymoma; Transfection | 2011 |
Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cells, Cultured; Dendritic Cells; Humans; Imiquimod; Injections, Subcutaneous; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasms; Skin; Species Specificity; Stem Cells | 2003 |
The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Animals; Bacterial Vaccines; Cancer Vaccines; Drug Synergism; Female; Imiquimod; Injections, Subcutaneous; Intramolecular Oxidoreductases; Listeria monocytogenes; Melanoma, Experimental; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Receptors, Cell Surface; Toll-Like Receptor 7; Vaccines, Synthetic | 2005 |
The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
Topics: Adjuvants, Immunologic; Adoptive Transfer; Aminoquinolines; Animals; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Survival; Central Nervous System Neoplasms; Dendritic Cells; Female; Flow Cytometry; gp100 Melanoma Antigen; Humans; Imaging, Three-Dimensional; Imiquimod; Immunohistochemistry; Immunotherapy, Adoptive; Lymphocyte Activation; Melanoma, Experimental; Membrane Glycoproteins; Mice; Neoplasm Proteins; Neoplasm Transplantation; T-Lymphocytes | 2006 |
Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Animals; Antigens, Neoplasm; Combined Modality Therapy; Cryosurgery; Female; Imiquimod; Immunity; Interferon Inducers; Interferon-gamma; Melanoma, Experimental; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Skin Neoplasms; Toll-Like Receptor 7; Vitiligo | 2007 |